Biogen Pharmachem Turns Profitable with Net Profit of ₹85.95 Lacs in FY26
Biogen Pharmachem Industries Limited reported a turnaround for the financial year ended March 31, 2026, posting a net profit of ₹85.95 lacs against a net loss of ₹29.27 lacs in the previous year. Revenue from operations increased to ₹255.80 lacs from ₹83.84 lacs, primarily due to other operating revenue. The company's paid-up equity share capital rose to ₹9,026.03 lacs during the year.
*this image is generated using AI for illustrative purposes only.
Biogen Pharmachem Industries Limited, formerly known as Sun Techno Overseas Limited, released its audited standalone financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results at its meeting held on May 14, 2026. The statutory auditors, M/s. Goenka Mehta & Associates, Chartered Accountants, issued an unmodified opinion on the financial results.
Full-Year Financial Performance
For the year ended March 31, 2026, Biogen Pharmachem recorded a notable turnaround, posting a net profit of ₹85.95 lacs against a net loss of ₹29.27 lacs in the year ended March 31, 2025. Revenue from operations rose sharply to ₹255.80 lacs from ₹83.84 lacs in the prior year, entirely driven by other operating revenue, as gross revenue from sale of products remained nil in both periods. Total expenses for FY26 stood at ₹160.13 lacs compared to ₹113.11 lacs in FY25, with employee benefit expenses increasing to ₹28.28 lacs from ₹16.79 lacs and other expenses rising to ₹131.85 lacs from ₹96.32 lacs. Tax expense of ₹9.73 lacs was recorded in FY26, with no tax expense in the prior year.
The following table summarises the key annual financial metrics (Rs. in lacs):
| Metric: | FY26 (Audited) | FY25 (Audited) |
|---|---|---|
| Revenue from Operations: | 255.80 | 83.84 |
| Total Income: | 255.80 | 83.84 |
| Employee Benefit Expense: | 28.28 | 16.79 |
| Other Expenses: | 131.85 | 96.32 |
| Total Expenses: | 160.13 | 113.11 |
| Profit/(Loss) Before Tax: | 95.67 | (29.27) |
| Tax Expense: | 9.73 | - |
| Net Profit/(Loss) After Tax: | 85.95 | (29.27) |
| Total Comprehensive Income: | 85.95 | (29.27) |
| Basic EPS (₹1/- each, not annualised): | 0.01 | (0.00) |
| Diluted EPS (₹1/- each, not annualised): | 0.01 | (0.00) |
Quarterly Financial Highlights
For the quarter ended March 31, 2026, the company reported a loss before tax of ₹35.88 lacs, compared to a profit of ₹117.78 lacs in the quarter ended March 31, 2025. Revenue from operations for Q4 FY26 stood at ₹57.82 lacs, down from ₹135.23 lacs in Q4 FY25, while total expenses surged to ₹93.70 lacs from ₹17.45 lacs in the same period last year, primarily on account of higher other expenses of ₹83.39 lacs. The preceding quarter ended December 31, 2025 recorded a profit of ₹46.23 lacs on revenue of ₹54.19 lacs.
| Metric: | Q4 FY26 (Audited) | Q3 FY26 (Unaudited) | Q4 FY25 (Audited) |
|---|---|---|---|
| Revenue from Operations: | 57.82 | 54.19 | 135.23 |
| Total Expenses: | 93.70 | 7.96 | 17.45 |
| Profit/(Loss) Before Tax: | (35.88) | 46.23 | 117.78 |
| Net Profit/(Loss) After Tax: | (35.88) | 46.23 | 117.78 |
Balance Sheet and Capital Position
As at March 31, 2026, total assets stood at ₹9,939.89 lacs compared to ₹9,201.77 lacs as at March 31, 2025. Non-current assets increased to ₹9,891.19 lacs from ₹8,934.90 lacs, supported by growth in non-current investments to ₹3,278.23 lacs from ₹2,384.41 lacs and non-current loans at ₹6,612.97 lacs versus ₹6,550.50 lacs. Current assets declined to ₹48.70 lacs from ₹266.86 lacs, with cash and cash equivalents reducing to ₹32.16 lacs from ₹197.59 lacs.
On the equity and liabilities side, paid-up equity share capital increased to ₹9,026.03 lacs from ₹6,526.03 lacs, reflecting share issuances during the year. Other equity stood at ₹882.68 lacs as at March 31, 2026, compared to ₹2,666.74 lacs in the prior year. Total shareholders' funds were ₹9,908.71 lacs versus ₹9,192.77 lacs previously.
| Balance Sheet Item: | 31st March 2026 (₹ lacs) | 31st March 2025 (₹ lacs) |
|---|---|---|
| Non-Current Assets: | 9,891.19 | 8,934.90 |
| Current Assets: | 48.70 | 266.86 |
| Total Assets: | 9,939.89 | 9,201.77 |
| Equity Share Capital: | 9,026.03 | 6,526.03 |
| Other Equity: | 882.68 | 2,666.74 |
| Shareholders' Funds: | 9,908.71 | 9,192.77 |
| Non-Current Liabilities: | 9.73 | - |
| Current Liabilities: | 21.45 | 9.00 |
| Total Equity and Liabilities: | 9,939.89 | 9,201.77 |
Cash Flow Summary
The standalone statement of cash flows, prepared under the indirect method as per Ind AS-7, showed net cash flow from operating activities of ₹156.83 lacs for the year ended March 31, 2026, compared to ₹108.20 lacs in the prior year. Net cash used in investing activities was ₹956.29 lacs, against ₹3,261.86 lacs in FY25, primarily reflecting investments in shares and long-term loan advances. Cash flow from financing activities amounted to ₹630.00 lacs, driven by proceeds from issue of shares, compared to ₹3,570.00 lacs in FY25. The closing cash and cash equivalents balance stood at ₹32.16 lacs as against an opening balance of ₹201.63 lacs.
Historical Stock Returns for Biogen Pharmachem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -14.58% | -18.00% | -48.10% | -54.95% | +86.36% |
Given that revenue from operations is entirely driven by 'other operating revenue' with zero product sales, what business model is Biogen Pharmachem pursuing and can this revenue stream sustain long-term profitability?
With equity share capital increasing by ₹2,500 lacs through share issuances while other equity dropped sharply from ₹2,666.74 lacs to ₹882.68 lacs, how might further dilutive capital raises impact minority shareholders?
Considering the sharp Q4 FY26 loss of ₹35.88 lacs driven by a surge in 'other expenses' to ₹83.39 lacs, what specific cost pressures could persist into FY27 and threaten the company's annual profitability trajectory?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
